A common diabetes medication may slow the progression of age-related vision loss, according to a new study from the University of Liverpool. Researchers analyzing retinal scans of nearly 2,000 diabetic patients found that those over 55 taking metformin were 37% less likely to develop an intermediate stage of age-related macular degeneration (AMD) over five years, compared to those not taking the drug.
The observational study, published this month, tracked patients undergoing routine check-ups for diabetic eye complications. Researchers assessed the presence and severity of AMD in the retinal images, comparing outcomes between metformin users and non-users, although accounting for factors like age, gender, and diabetes duration. The findings, described as a “promising step” in ophthalmology, suggest metformin’s anti-inflammatory and anti-aging properties may protect retinal cells.
“The results are promising, and suggest metformin may have the potential to save the sight of many,” said Dr. Nick Parr, an ophthalmologist at the University of Liverpool, according to reports from Syrian news agency SANA. He emphasized the necessitate for rigorous clinical trials to test the drug’s effectiveness as a treatment for AMD.
While metformin is generally considered safe, potential side effects include digestive issues and, in some cases, vitamin B12 deficiency, according to reports. The study, however, did not collect detailed data on metformin dosages or patient adherence to the medication regimen.
The research builds on earlier findings from February 3, 2026, reported by Al Arabiya, which indicated the potential of metformin to slow the development of AMD, a leading cause of blindness in Western countries. Alweeam.com.sa reported similar findings, noting the 37% reduction in AMD risk among diabetic patients over 55 taking metformin over a five-year period. Okaz.com.sa also reported on the study, reiterating the 37% risk reduction.
Researchers caution that the study is observational and does not prove a direct causal link between metformin apply and reduced AMD risk. The impact of the drug on individuals without diabetes remains unknown. A formal clinical trial is planned to further investigate metformin’s potential as an AMD treatment.
